Fibrosis occurs in a variety of organs and frequently brings great harm to patients,
even contributes to their death. Despite great efforts made in the field of fibrosis over the past
decades and considerable understanding of the pathogenesis of fibrotic reactions attained,
there is still lack of effective anti-fibrotic treatments. A growing body of evidence indicates a
significant anti-fibrotic potential of activated soluble guanylate cyclase (sGC), which emphasizes
the importance of sGC in fibrogenesis of diverse organs including skin, kidney, liver and
lung. While sGC has been well known for its role in the regulation of vascular tone and vascular
remodeling, its possible implication in fibrosis remains to be illustrated. Emerging evidence
in recent years provides new insights into anti-fibrotic effect of sGC stimulation by
blocking non-canonical TGF-β signaling. In this review we will discuss the key role of sGC
and its mechanism of action in fibrosis. Herein, sGC signaling pathway may represent a
promising target for treating tissue fibrosis.
Keywords: Fibrotic diseases, soluble guanylate cyclase, TGF-β signaling pathway, extracellular regulated protein
kinases, soluble guanylate cyclase modulators, mechanism of action.
Rights & PermissionsPrintExport